Common Stock, par value $0.007 per share
- Symbol
- BIAF
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 8.01, 9.01 · 8-K
BIAFNASDAQEQUITYCurrent
Item 8.01. Other Events. On November 11, 2026, bioAffinity Technologies, Inc., a Delaware corporation (the “Company”), issued a press release announcing that a record number of CyPath ® Lung tests were performed in October 2026, marking the highest monthly testing volume for the Company’s noninvasive lung cancer test.…
bioAffinity Technologies, Inc. addresses the need for non-invasive diagnosis of early-stage cancer and other diseases of the lung and broad-spectrum cancer treatments. The Company’s first product, CyPath ® Lung, is a non-invasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath® Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies. For more information, visit www.bioaffinitytech.com.
bioAffinity Technologies, Inc. · 8-K · Filed 2026-11-17
Exhibit 99.1 bioAffinity Technologies Reports Record Monthly Testing Volume in October for Its Noninvasive CyPath® Lung Test October testing volume equals approximately 45% of all tests performed in the previous quarter SAN ANTONIO, Texas - November 11, 2026 - bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company developing noninvasive healthcare solutions for the early detection and monitoring of lung disease and topically delivered therapeutics for skin cancer, today announced that a record number of CyPath® Lung tests were performed in October 2026, marking the highest monthly testing volume for the Company’s noninvasive lung cancer test. The October results demonstrate continued growth in test utilization by both established and newly ordering physicians. In October 2026, 235 CyPath Lung tests were performed, representing a 29% increase compared with October 2025. October 2026 testing volume was equivalent to approximately 45% of the total number of tests performed in Q3 2026. “October’s testing volume reflects our efforts to expand the commercial reach of CyPath Lung,” said Maria Zannes, President and Chief Executive Officer of bioAffinity Technolo…
Open exhibit ↗